Princeton Global Asset Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-10,474
Closed -$18.1K 670
2024
Q2
$18.1K Hold
10,474
﹤0.01% 398
2024
Q1
$25K Hold
10,474
0.01% 338
2023
Q4
$34.9K Hold
10,474
0.01% 303
2023
Q3
$39.2K Buy
+10,474
New +$48.4K 0.01% 273

Other funds holding CHRS

Princeton Global Asset Management's CHRS Position: Q3 2024 in Review

Princeton Global Asset Management sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 10,474 shares — an estimated $18.1K sold.

Princeton Global Asset Management first reported a position in CHRS in Q3 2023 and held it in 4 quarters. The position peaked at $39.2K in Q3 2023. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Princeton Global Asset Management reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 10,474 Coherus Oncology shares in Q3 2024, an estimated $18.1K.
  • Princeton Global Asset Management first reported a position in Coherus Oncology in Q3 2023 and held it in 4 quarters.
  • Princeton Global Asset Management's Coherus Oncology position peaked at $39.2K in Q3 2023.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Princeton Global Asset Management's 13F filing for Q3 2024, filed 29 Oct 2024.